RIBOTECT

Welcome to the Brand page for “RIBOTECT”, which is offered here for Chemical reagents for medical and veterinary purposes; medical and pharmaceutical preparations comprising liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or lipid-based emulsions for the treatment and prevention of cancerous diseases, infectious diseases, autoimmune disorders, genetic defects or metabolic disorders; medical and pharmaceutical preparations comprising, in particular, liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or lipid-based emulsions and comprising additional active ingredients, in particular proteins or nucleid acids for the treatment and prevention of cancerous diseases, infectious diseases, autoimmune disorders, genetic defects or metabolic disorders; carriers and carrier systems, drug delivery agents in the form of powders, tablets, liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or lipid-based emulsions and capsules that provide controlled release of the active ingredients for pharmaceuticals for use in the treatment of cancer, infectious diseases, autoimmune disorders, genetic defects, and metabolic disorders;medical and veterinary services in connection with cancer diseases, infectious diseases, autoimmune disorders, genetic defects, and metabolic disorders;scientific research for medical and veterinary purposes, in particular for treatment of cancer, infectious diseases, autoimmune disorders, genetic defects, and metabolic disorders, using liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or emulsions;.

Its status is currently believed to be active. Its class is unavailable. “RIBOTECT” is believed to be currently owned by “BioNTech SE”.